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Introduction and Aims: Cystatin C is increasingly used in equations for estimating
GFR. The dependence of cysC results upon the analytical method has been a major
source of controversy and uncertainty.
Methods: CysC was measured with non-standardized turbidimetric Roche Generation
1 and standardized nephelometric Siemens assays in 3666 blood samples of the Berlin
Initiative Study. Additionally, cysC was measured with standardized Roche Generation
2 and Siemens in 567 samples. CysC-based eGFR was assessed with CKD-EPIcys
(Chronic Kidney Disease Epidemiology) and CAPA (Caucasian, Asian, Pediatric,
Adult) equations and the impact of the assays on eGFR was determined. Equation
performance compared to mGFR was evaluated.
Results: Concordance of Roche Gen2 and Siemens was high with median difference of
0.003±0.13mg/L (limits of agreement: -0.12 to 0.12) and Passing Bablok correlation
was essentially perfect Figure 1:Bland and Altman of PETIA Roche Gen2 versus PENIA
Siemens cystatin C (mg/L) assay (n=567). The bias is represented by the solid middle line
(0.003 mg/L). The upper (0.12 mg/L) and lower limits (-0.12 mg/L) of the interval of
agreement are represented by the dashed lines.
Non-standardized Roche Gen1 assay showed worse concordance with Siemens:
median difference was 0.08±0.13mg/L (limits of agreement: -0.18 to 0.34) and Passing
Bablok correlation was inferior Figure 2: Bland and Altman of PETIA Roche Gen1
versus PENIA Siemens cystatin C (mg/L) assay (n=3666). The bias is represented by the
solid middle line (0.08 mg/L). The upper (0.38 mg/L) and lower limits (-0.18 mg/L) of the
interval of agreement are represented by the dashed lines.
Mean difference (±SD) of estimated GFRCKD-EPI was 0±4mL/min/1.73m² for Gen2 and
Siemens as compared to -5±8 with Gen1. Performance of cystatin C-based
GFR-equations was not influenced by the choice of Siemens or Gen2 assays.
Conclusions: Standardization of Roche Gen2 assay has led to improved accuracy of
cysC measurement procedure compared to Siemens suggesting only negligible method
bias and resulting in equal performance of both assays when estimating KF. This work
indicates that successful calibration has led to major progress in cysC analysis.
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